Form 4: Lyell Immunopharma CEO Sells Shares for Tax Obligation
Insider Transaction Report
Lyell Immunopharma's President and CEO, Lynn Seely, sold 412 shares of common stock at $16.11 per share to cover tax withholding obligations.
Summary
- Lynn Seely, who serves as a Director, President, and CEO of Lyell Immunopharma, Inc. (LYEL), reported a transaction on November 10, 2025.
- Seely sold 412 shares of Lyell Immunopharma common stock at a price of $16.11 per share.
- This sale was an automatic transaction executed to cover tax withholding obligations associated with the settlement of vested restricted stock units.
- Following this reported transaction, Lynn Seely beneficially owns 67,159 shares of Lyell Immunopharma common stock directly.
Sentiment
Score: 5
Explanation: The transaction is a routine, non-discretionary sale to cover tax obligations from vested restricted stock units, indicating a neutral sentiment regarding the company's operational performance or future prospects.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This insider transaction is a routine event for a publicly traded company's executive and does not provide specific insights into broader industry trends or competitive landscape.
Stakeholder Impact
- Minimal impact on shareholders as this is a routine, non-discretionary sale for tax purposes, not indicative of a change in management's confidence or company fundamentals.
Key Dates
| Date | Description |
|---|---|
| 11/10/2025 | Date of the common stock transaction (sale). |
| 11/12/2025 | Date the Form 4 was filed with the SEC. |
Keywords
Lyell Immunopharma, LYEL, Insider Trading, Form 4, Lynn Seely, Stock Sale, Tax Withholding, Restricted Stock Units, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.